Ncats project phase II supplement - target validation and therapeutic evaluation in NGLY1DEFICIENT chip-based models, POP: 6/21/2021-10/20/2021
Ended Purchase Order Awarded Last action
- Contract number
- 75N95021P00296
- Awardee
-
Hesperos, Inc. UEI R1LSLA5YJMJ9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $142,843
Award facts
- Opportunity
-
- NCATS Project Phase II Supplement – Target Validation and therapeutic evaluation in NGLY1 deficient chip-based models Solicitation · 75N95021Q00149 · Posted Jun 8, 2021
- Contract value 100% obligated
- $142,843.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Orlando, FL 32826, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $142,843 |
About this award
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $142,843.00 firm-fixed-price purchase order to Hesperos, Inc., a leading company in organ-on-a-chip technology, to provide scientific testing services. The contract is for the target validation and therapeutic evaluation of drug compound TRND00601748-01 in NGLY1 deficient cell-based models, including motoneurons and neuromuscular junction models. This non-competitive acquisition is a Phase II supplement to an existing project focused on NGLY1 deficiency, a rare genetic disease affecting motor function. The contract has a period of performance from June 21, 2021 to October 20, 2021 and does not have a set-aside designation.
Quick answers
Who was awarded contract 75N95021P00296?
75N95021P00296 was awarded to Hesperos, Inc. by National Institute on Drug Abuse (National Institutes of Health) on June 21, 2021.
How much is contract 75N95021P00296 worth?
The government has obligated $142,843 on 75N95021P00296.
Which agency awarded contract 75N95021P00296?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95021P00296, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95021P00296 competed?
The extent of competition for 75N95021P00296 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award